Navigation Links
Researcher targets gene regulators on link between arsenic, cancer
Date:7/14/2010

EAST LANSING, Mich. To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.

Chengfeng Yang, a physiology assistant professor with the College of Veterinary Medicine and MSU's Center for Integrative Toxicology, will be studying the role of very small ribonucleic acids called microRNAs. These microRNAs regulate genes, which control how a cell behaves.

The research project, which will study those processes in cultured human cells and mice, is funded by the National Institutes of Health.

"Arsenic is one of the most common environmental pollutants, and long-term arsenic exposure through drinking water is associated with increased risk of lung cancers specifically and some other cancers as well," Yang said. "The long-term goal of this study is to determine the mechanism by which this happens and to identify targets for the treatment and prevention of cancers resulting from arsenic exposure."

Since the levels of microRNAs are different when comparing normal tissue cells to cancer cells, Yang and his team are trying to determine if that difference is because of the tumor or if it is what caused the tumor in the first place.

"Does microRNA play a role in tumor development? Can carcinogens such as arsenic cause the deregulation of microRNA that leads to cancer development? That's what we need to find out," Yang said.

To accomplish that, Yang will look at two specific microRNAs miRNA200b and miRNA200c and the role they play in converting normal human bronchial epithelial cells to tumor cells when exposed to arsenic. Those specific microRNAs were chosen because during screening, they were the only two that were different when comparing normal cells with cells transformed by cells.

"A single microRNA has the ability to regulate more than 100 gene functions, playing an important role in cell behavior and whether cells function normally or potentially change to a cancerous cell," Yang said. "More than one-third of all human genes are believed to be regulated by microRNAs, and when microRNA levels are too high or too low, they disrupt the normal function of cells and lead to disease."

Uncovering how microRNAs react to carcinogens and lead to tumor development could help researchers discover biomarkers and identify people who may be more prone to develop tumors.

"With this information, we could potentially diagnose and treat people much sooner," Yang said.

As part of his project, Yang also will investigate the role of two genes called ZEB1 and ZEB2 in this process, because the appearance of these two genes can cause the depletion of miRNA-200b and miRNA-200c. He will further examine the role of these two genes in arsenic-induced tumors by studying mice with the ZEB1 and ZEB2 genes removed.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. Researchers study relationship of oral cancers and periodontal disease
2. HIV care providers and researchers applaud release of national HIV/AIDS strategy
3. Researchers envision better disease surveillance to improve public health
4. U-M researchers identify gene mutation that causes rare form of deafness
5. MIT researchers find that Sirtuin1 may boost memory and learning ability
6. OU researcher developing novel therapy for Alzheimers disease
7. Researchers identify factors behind blood-making stem cells
8. Parkinsons Transplant Mystery Solved, Researchers Say
9. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
10. Researchers suggest new paradigm for breast cancer screening
11. Of lice and man: Researchers sequence human body louse genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher targets gene regulators on link between arsenic, cancer
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: